Study of lymph node MRI (magnetic resonance imaging) agent completed:
This article was originally published in Clinica
Advanced Magnetics has said it will file a new drug application with the FDA next year for its MRI contrast agent Combidex, following the completion of Phase III clinical trials. The Cambridge, Massachusetts-based company plans to market the agent for assisting in the diagnosis and staging of metastatic disease in lymph nodes as well as for detecting and characterising liver lesions.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.